Cardiorenal Syndrome Type 1 Clinical Trial
Official title:
Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome
A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.
n/a